Neuroleptic dysphoria: revisiting the concept 50 years later

被引:24
作者
Awad, AG
Voruganti, LNP
机构
[1] Univ Toronto, Dept Psychiat, Toronto, ON M5S 1A8, Canada
[2] Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada
[3] McMaster Univ, Dept Psychiat & Behav Sci, Schizophrenia Res Program, Hamilton, ON L8S 4L8, Canada
关键词
schizophrenia; antipsychotics; neuroleptic dysphoria; dopamine; subjective tolerability;
D O I
10.1111/j.1600-0447.2005.00539.x
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: To review the concept of neuroleptic dysphoria, its historical development and the current state of the art. Method: This paper is based on extensive but selective literature review and also draws on our extensive clinical and research experiences. Results: Although the construct of neuroleptic dysphoria was recognized shortly following the introduction of the first antipsychotic, chlorpromazine, it took several years for the concept to receive adequate research and clinical attention. Without having direct evidence to link neuroleptic dysphoria to dopamine, it was generally understood that dopamine played a significant role in its genesis. In recent neuroimaging studies and dopamine depletion strategies, the role of dopamine in the genesis of neuroleptic dysphoria has been directly confirmed. Conclusion: Neuroleptic dysphoria is a valid construct, which has significant implications for treatment and outcome. It is now clear that it relates to dopamine activities in the nigrostriatal complex. Recent research has also raised the issue of whether neuroleptic dysphoria is a variant of extrapyramidal symptoms. Meanwhile, the role of dopamine in both the genesis of neuroleptic dysphoria and addictive behaviour has raised the issue of both conditions being different facets of the schizophrenic disease process. The recent interface of addiction and psychiatry research may have opened a new science: the science of subjective tolerability disorders.
引用
收藏
页码:6 / 13
页数:8
相关论文
共 65 条
[1]   Assessment of the patient's subjective experience in acute neuroleptic treatment: Implications for compliance and outcome [J].
Awad, AG ;
Voruganti, LNP ;
Heslegrave, RJ ;
Hogan, TP .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1996, 11 :55-59
[2]   Intervention research in psychosis: Issues related to the assessment of quality of life [J].
Awad, AG ;
Voruganti, LNP .
SCHIZOPHRENIA BULLETIN, 2000, 26 (03) :557-564
[3]   Patients subjective experiences on antipsychotic medications: Implications for outcome and quality of life [J].
Awad, AG ;
Hogan, TP ;
Voruganti, LNP ;
Heslegrave, RJ .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1995, 10 :123-132
[4]   EARLY TREATMENT EVENTS AND PREDICTION OF RESPONSE TO NEUROLEPTICS IN SCHIZOPHRENIA [J].
AWAD, AG ;
HOGAN, TP .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 1985, 9 (5-6) :585-588
[5]   SUBJECTIVE RESPONSE TO NEUROLEPTICS IN SCHIZOPHRENIA [J].
AWAD, AG .
SCHIZOPHRENIA BULLETIN, 1993, 19 (03) :609-618
[6]   Antipsychotic medications: compliance and attitudes towards treatment [J].
Awad, AG .
CURRENT OPINION IN PSYCHIATRY, 2004, 17 (02) :75-80
[7]  
Awad AG, 1997, QUAL LIFE RES, V6, P21
[8]   Quality of life and new antipsychotics in schizophrenia - Are patients better off? [J].
Awad, AG ;
Voruganti, LNP .
INTERNATIONAL JOURNAL OF SOCIAL PSYCHIATRY, 1999, 45 (04) :268-275
[9]  
AWAD AG, 1999, CLEAR PERSPECTIVES M, P1
[10]  
AWAD AG, 2004, CAN J PSYCHIAT, V47, P171